Healthcare / Pharmaceutical RetailersSaudi
$48.02
-0.50 (-1.03%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $490.0M · quality 67.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
46/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.1B
P/E
11.2x
↓EV/EBITDA
6.8x
↓ROE
25.4%
↑Gross Margin
35.5%
↓Debt/Equity
1.44
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
+8.6%
FCF CAGR
+9.1%
FCF margin
7.0%
FCF / Net income
1.23x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $6.45B · net income $370.1M · FCF $454.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6.45B | $6.45B | $5.74B | $5.37B | $5.03B |
| Net Income | $370.1M | $370.1M | $329.2M | $305.4M | $239.1M |
| EBITDA | $896.7M | $896.7M | $830.4M | $789.4M | $662.7M |
| EPS | 4.35 | 4.35 | 3.87 | 3.59 | 2.81 |
| Gross Margin | 35.5% | 35.5% | 36.7% | 37.6% | 37.6% |
| Operating Margin | 8.3% | 8.3% | 8.7% | 7.0% | 5.4% |
| Net Margin | 5.7% | 5.7% | 5.7% | 5.7% | 4.8% |
| Balance Sheet | |||||
| Debt/Equity | 1.44 | 1.44 | 1.75 | 2.40 | 2.22 |
| Current Ratio | 1.21 | 1.21 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $454.6M | $454.6M | $502.1M | $490.0M | $350.0M |
| Returns | |||||
| ROE | 25.4% | 25.4% | 25.1% | 27.9% | 24.2% |
| Valuation | |||||
| P/E | 11.19 | 11.19 | 28.27 | 20.61 | — |
| EV/EBITDA | 6.84 | 6.84 | 13.90 | 11.13 | — |
| P/B | 2.80 | 2.80 | 7.08 | 5.74 | — |
| Growth & Yield | |||||
| Revenue Growth | 12.4% | 12.4% | 6.9% | 6.7% | — |
| EPS Growth | 12.4% | 12.4% | 7.8% | 27.6% | — |
| Dividend Yield | 6.5% | 6.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-0.7%
EPS terminal req.
$4.26
Spread vs growth
13.1%
5Y implied EPS CAGR
3.5%
EPS terminal req.
$5.16
Spread vs growth
8.9%
10Y implied EPS CAGR
6.7%
EPS terminal req.
$8.30
Spread vs growth
5.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-31.4%
Start / end P/E
20.1x → 11.1x
EPS bridge
3.87 → 4.35
Residual
-5.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.